The benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

Roy S. Herbst, MD, PhD, explains the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC at ASCO 2018.

Author: obr
Added: 07/18/2018

Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts